<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01238315</url>
  </required_header>
  <id_info>
    <org_study_id>CL-N03-NCL</org_study_id>
    <nct_id>NCT01238315</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis</brief_title>
  <official_title>A Phase Ib Study of the Safety and Preliminary Efficacy of Allogeneic Intracerebral Human Central Nervous System Stem Cell Transplantation in Subjects With Non-Refractory Infantile and Late Infantile Neuronal Ceroid Lipofuscinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>StemCells, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>StemCells, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase Ib study is to determine if &quot;Human Central Nervous  System Stem
      Cells&quot;(HuCNS-SC) is safe to be transplanted in subjects with infantile and late infantile
      neuronal ceroid lipofuscinosis. The study will also measure post-transplantation disease
      progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation in this study will involve screening assessments, surgery to implant HuCNS-SC,
      medication to suppress immune system and a series of follow-up assessments.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of timely patient accrual
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Safety assessment through clinical, neurological and MRI evaluation.</measure>
    <time_frame>one year following transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in neurological, neuropsychological development, MRI and MRS</measure>
    <time_frame>one year following transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neuronal Ceroid Lipofuscinosis</condition>
  <arm_group>
    <arm_group_label>HuCNS-SC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HuCNS-SC</intervention_name>
    <description>Surgery to implant human CNS stem cells</description>
    <arm_group_label>HuCNS-SC</arm_group_label>
    <other_name>human neural stem cells</other_name>
    <other_name>stem cells</other_name>
    <other_name>neural stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 months to 6 years

          -  Male or female

          -  Clinical diagnosis of Infantile neuronal ceroid lipofuscinosis or late infantile
             neuronal ceroid lipofuscinosis

          -  CLN1 or CLN2 mutation

        Exclusion Criteria:

          -  Previously received an organ, tissue or bone marrow transplantation

          -  Previously participated in any gene or cell therapy study

          -  Infection with hepatitis virus, cytomegalovirus, Epstein-Barr virus, or Human
             Immunodeficiency Virus (HIV)

          -  Current or prior cancer

          -  Bleeding disorder

          -  Unable to have an MRI scan
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Selden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stemcellsinc.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ohsu.edu/research/rda/so/viewstudy.php?id=IRB00006480</url>
    <description>Infantile and Late Infantile Neuronal Ceroid Lipofuscinosis</description>
  </link>
  <verification_date>April 2011</verification_date>
  <lastchanged_date>April 8, 2011</lastchanged_date>
  <firstreceived_date>November 5, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Stephen Huhn, MD</name_title>
    <organization>StemCells Inc.</organization>
  </responsible_party>
  <keyword>Batten's disease</keyword>
  <keyword>INCL</keyword>
  <keyword>LINCL</keyword>
  <keyword>Neuronal Ceroid Lipofuscinosis</keyword>
  <keyword>NCL</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
  </condition_browse>
</clinical_study>
